These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36979848)

  • 1. Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study.
    Katsuyama H; Hakoshima M; Umeyama S; Iida S; Adachi H; Yanai H
    Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
    Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
    Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study.
    Tanaka K; Okada Y; Tokutsu A; Tanaka Y
    Sci Rep; 2022 Jan; 12(1):154. PubMed ID: 34997102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics.
    García-Pérez LE; Boye KS; Rosilio M; Jung H; Heitmann E; Norrbacka K; Federici MO; Gentilella R; Guerci B; Giorgino F; Aigner U; Sapin H
    Diabetes Ther; 2021 Jul; 12(7):1929-1946. PubMed ID: 34097244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins.
    Hasegawa Y; Hori M; Nakagami T; Harada-Shiba M; Uchigata Y
    J Clin Lipidol; 2018; 12(1):62-69.e1. PubMed ID: 29217412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice.
    Lee J; Cho YK; Kim HS; Jung CH; Park JY; Lee WJ
    Diabetes Metab Syndr Obes; 2019; 12():2745-2753. PubMed ID: 31920354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching from insulin to dulaglutide therapy in patients with type 2 diabetes: A real-world data study.
    Lee J; Kim HS; Jung CH; Park JY; Lee WJ
    Diabetes Metab Res Rev; 2021 Nov; 37(8):e3466. PubMed ID: 33957706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial.
    Tuttolomondo A; Cirrincione A; Casuccio A; Del Cuore A; Daidone M; Di Chiara T; Di Raimondo D; Corte VD; Maida C; Simonetta I; Scaglione S; Pinto A
    Cardiovasc Diabetol; 2021 Jan; 20(1):1. PubMed ID: 33397395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes.
    Berra CC; Resi V; Mirani M; Folini L; Rossi A; Solerte SB; Fiorina P
    Pharmacol Res; 2020 Sep; 159():104996. PubMed ID: 32574827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved Clinical Outcomes with Dulaglutide as Add-on Medication to Oral Antidiabetic Drugs with or Without Insulin in Overweight Indian Patients with Type 2 Diabetes Mellitus: Retrospective Study in a Real-World Setting.
    Ghosh A; Nair R
    Curr Diabetes Rev; 2020; 16(5):490-496. PubMed ID: 31686642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Once-Weekly Semaglutide on Cardiovascular Risk Factors and Metabolic Dysfunction-Associated Steatotic Liver Disease in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study Based on Real-World Data.
    Katsuyama H; Hakoshima M; Kaji E; Mino M; Kakazu E; Iida S; Adachi H; Kanto T; Yanai H
    Biomedicines; 2024 May; 12(5):. PubMed ID: 38790963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of Dulaglutide in the Real World and in Special Populations of Type 2 Diabetic Patients.
    Morieri ML; Frison V; Rigato M; D'Ambrosio M; Tadiotto F; Paccagnella A; Simioni N; Lapolla A; Avogaro A; Fadini GP
    J Clin Endocrinol Metab; 2020 Jul; 105(7):. PubMed ID: 32301492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain.
    Norrbacka K; Sicras-Mainar A; Lebrec J; Artime E; Díaz S; Tofé-Povedano S; Hernández I; Romera I
    Diabetes Ther; 2021 May; 12(5):1535-1551. PubMed ID: 33860927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study.
    Sanada J; Kimura T; Shimoda M; Tomita A; Fushimi Y; Kinoshita T; Obata A; Okauchi S; Hirukawa H; Kohara K; Tatsumi F; Nakanishi S; Mune T; Kaku K; Kaneto H
    Front Endocrinol (Lausanne); 2021; 12():714447. PubMed ID: 34484124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dulaglutide Shows Sustained Reduction in Glycosylated Hemoglobin Values: 2-Year US Real-world Study Results.
    Mody R; Yu M; Grabner M; Boye K; Teng CC; Kwan AYM
    Clin Ther; 2020 Nov; 42(11):2184-2195. PubMed ID: 33256915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study.
    Jain AB; Kanters S; Khurana R; Kissock J; Severin N; Stafford SG
    Diabetes Ther; 2021 Feb; 12(2):527-536. PubMed ID: 33367981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial.
    Inagaki N; Takeuchi M; Oura T; Imaoka T; Seino Y
    Lancet Diabetes Endocrinol; 2022 Sep; 10(9):623-633. PubMed ID: 35914543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of 21 randomized controlled trials.
    Qie S; Li X; Wang X; Liu Y; Li J; Liu G
    Endocrine; 2020 Jun; 68(3):508-517. PubMed ID: 31927749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.
    Zimner Rapuch S; Divino V; Norrbacka K; Boye K; Lebrec J; Rosilio M; DeKoven M; Guerci B
    Diabetes Ther; 2021 May; 12(5):1553-1567. PubMed ID: 33864629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.